209224-91-9

Basic information

• Product Name: 5-(3-TRIFLUOROMETHYL-PHENYL)-2H-PYRAZOL-3-YLAMINE
• Synonyms: 3-[3-(TRIFLUOROMETHYL)PHENYL]-1H-PYRAZOL-5-YLAMINE;5-(3-TRIFLUOROMETHYL-PHENYL)-2H-PYRAZOL-3-YLAMINE;3-[3-(Trifluoromethyl)phenyl]-1H-pyrazol-5-amine, 3-(5-Amino-1H-pyrazol-3-yl)benzotrifluoride;5-[3-(trifluoromethyl)phenyl]-1H-Pyrazol-3-amine
• CAS NO: 209224-91-9
• Molecular Formula: C₁₀H₈F₃N₃
• Molecular Weight: 227.19
• Mol File: 209224-91-9.mol
• Article Data: 7

Chemical Properties

• Melting Point: 130-132°C
• Boiling Point: 425.1°C at 760 mmHg
• Flash Point: 210.9°C
• Appearance: /
• Density: 1.401g/cm³
• Vapor Pressure: 1.96E-07mmHg at 25°C
• Refractive Index: 1.562
• CAS DataBase Reference: 5-(3-TRIFLUOROMETHYL-PHENYL)-2H-PYRAZOL-3-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(3-TRIFLUOROMETHYL-PHENYL)-2H-PYRAZOL-3-YLAMINE(209224-91-9)
• EPA Substance Registry System: 5-(3-TRIFLUOROMETHYL-PHENYL)-2H-PYRAZOL-3-YLAMINE(209224-91-9)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 209224-91-9(Hazardous Substances Data)

Usage

General Description

5-(3-trifluoromethyl-phenyl)-2H-pyrazol-3-ylamine is a chemical compound with the molecular formula C10H8F3N3. It belongs to the class of pyrazole compounds and contains a trifluoromethyl-phenyl group and a pyrazol-3-ylamine group. It is commonly used in medicinal and pharmaceutical research as it exhibits various pharmacological properties. This chemical compound has been studied for its potential use as a therapeutic agent in the treatment of various diseases, including cancer, inflammation, and neurological disorders. Its unique molecular structure and properties make it a valuable component in drug discovery and development.

InChI:InChI=1/C10H8F3N3/c11-10(12,13)7-3-1-2-6(4-7)8-5-9(14)16-15-8/h1-5H,(H3,14,15,16)

Upstream product

• 2003-10-3 2-bromo-1-[3-(trifluoromethyl)phenyl]ethanone 
• 27328-86-5 3-trifluoromethylbenzoylacetonitrile 
• 387824-53-5 5-(3-(trifluoromethyl)phenyl)isoxazole 

Downstream Products

• 1141401-99-1 N-(3-(3-(trifluoromethyl)phenyl)-1H-pyrazol-5-yl)-2-mercaptoacetamide 
• 1262406-08-5 4-(trifluoromethyl)-3-(3-(trifluoromethyl)phenyl)-1,7-dihydro-6H-pyrazolo[3,4-b]pyridin-6-one 

Relevant articles and documents

Synthesis and biological evaluation of 7-(aminoalkyl)pyrazolo[1,5-a]pyrimidine derivatives as cathepsin K inhibitors

A series of novel 7-aminoalkyl substituted pyrazolo[1,5-a]pyrimidine derivatives were synthesized and tested for inhibition of cathepsin K. The synthetic methodology comprises cyclization of 5-aminopyrazoles with N-Boc-α-amino acid-derived ynones followed by transformation of the ester and the Boc-amino functions. It allows for easy diversification of the pyrazolo[1,5-a]pyrimidine scaffold at various positions. Molecular docking studies with pyrazolo[1,5-a]pyrimidine derivatives were also performed to elucidate the binding mode in the active site of cathepsin K. The synthesized compounds exhibited moderate inhibition activity (Ki ≥ 77 μM).

Synthesis of Aminopyrazoles from Isoxazoles: Comparison of Preparative Methods by in situ NMR Analysis

A single-step method and a two-step method for the synthesis of aminopyrazoles from isoxazoles are presented and compared. Based on in situ NMR monitoring, both processes proceed through a ketonitrile. In the single-step process, hydrazine serves to both open the isoxazole to the unisolated ketonitrile intermediate and form the aminopyrazole. The two-step process involves ring opening of the isoxazole by deprotonation with hydroxide to generate the ketonitrile followed by the addition of acetic acid and hydrazine to form the aminopyrazole.

Design, synthesis, and evaluation of 2-aryl-7-(3′,4′-dialkoxyphenyl)-pyrazolo[1,5-a]pyrimidines as novel PDE-4 inhibitors

Described herein is design, synthesis, and biological evaluation of novel series of 2-aryl-7-(3′,4′-dialkoxyphenyl)-pyrazolo[1,5-a]pyrimidines acting as inhibitors of type 4 phosphodiesterase (PDE4) which is known as a good target for the treatment of asthma and COPD. For this purpose, structure optimization was conducted with the aid of structure-based drug design using the known X-ray crystallography. Also, biological effects of these compounds on the target enzyme were evaluated by using in vitro assays, leading to the potent and selective PDE-4 inhibitor (IC50 10 nM).